Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 9, 2008, Pages 721-729

  Bergman, Annika C S ^a   Hjelmgren, Jonas ^a   Örtqvist, Åke ^a   Wisløff, Torbjørn ^b,c   Sønbø Kristiansen, Ivar ^b,c   Diaz Högberg, Liselotte ^d   M S Persson, Kristina ^e   Persson, Ulf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

^c UNIVERSITY OF OSLO   (Norway)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e Department of Communicable Diseases Control and Prevention ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ADULT; AGED; ARTICLE; BACTERIAL MENINGITIS; CHILD; CHILDHOOD MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HERD IMMUNITY; HOSPITALIZATION; HUMAN; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEPTICEMIA; SIMULATION; STREPTOCOCCUS INFECTION; SWEDEN; VACCINATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BACTEREMIA; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MARKOV CHAINS; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SWEDEN; VACCINATION; YOUNG ADULT;

EID: 50549092584     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540802014872     Document Type: Article

References (28)

1. Klein, JO. (1981) The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis, 3, pp. 246-253.
2. Hausdorff, WP, Bryant, J., Kloek, C., Paradiso, PR and Siber, GR. (2000) The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use; part II. Clin Infect Dis, 30, pp. 122-140.
3. Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P. Hansen, JR et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J, 19, pp. 187-195.
4. Black, SB, Shinefield, HR, Ling, S., Hansen, J., Fireman, B. Spring, D. et al. (2002) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 y of age for prevention of pneumonia. Pediatr Infect Dis J, 21, pp. 810-815.
5. Hansen, J., Black, S., Shinefield, H., Cherian, T., Benson, J. Fireman, B. et al. (2006) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 y of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J, 25, pp. 779-781.
6. Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Haapakoski, J. Herva, E. et al. (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med, 344, pp. 403-409.
7. Whitney, CG, Farley, MM, Hadler, J., Harrison, LH, Bennett, NM Lynfield, R. et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med, 348, pp. 1737-1746.
8. Grijalva, CG, Nuorti, JP, Arbogast, PG, Martin, SW, Edwards, KM and Griffin, MR. (2007) Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet, 369, pp. 1179-1186.
9. McIntosh, ED, Conway, P., Willingham, J. and Lloyd, A. (2003) The cost burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine, 21, pp. 2564-2572.
10. Wisloff, T., Abrahamsen, TG, Bergsaker, MA, Lovoll, O., Moller, P., Pedersen, MK and Kristiansen, IS (2006) Cost-effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination programme. Vaccine, 24, pp. 5690-5699.
11. Whitney, CG, Pilishvili, T., Farley, MM, Schaffner, W., Craig, AS Lynfield, R. et al. (2006) Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: A matched case-control study. Lancet, 368, pp. 1495-1502.
12. Dahl, MS, Trollfors, B., Claesson, BA, Brandberg, LL and Rosengren, A. (2001) Invasive pneumococcal infections in south-western Sweden: A second follow-up period of 15 y. Scand J Infect Dis, 33, pp. 667-672.
13. Brandenburg, JA, Marrie, TJ, Coley, CM, Singer, DE, Obrosky, DS, Kapoor, WN and Fine, MJ. (2000) Clinical presentation: Processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med, 15, pp. 638-646.
14. Joki-Erkkila, VP, Laippala, P. and Pukander, J. (1998) Increase in paediatric acute otitis media diagnosed by primary care in 2 Finnish municipalities: 1994-1995 versus 1978-1979. Epidemiol Infect, 121, pp. 529-534.
15. Treatment for acute inflammation of the middle ear, Programme and Lectures. Consensus development conference
16. Sade, J., Russo, E., Fuchs, C. and Cohen, D. (2003) Is secretory otitis media a single disease entity?. Ann Otol Rhinol Laryngol, 112, pp. 342-347.
17. Vassbotn, FS., Klausen, OG., Lind, O. and Moller, P. (2002) Acute mastoiditis in a Norwegian population: A 20-y retrospective study. Int J Pediatr Otorhinolaryngol, 62, pp. 237-242.
18. Straetemans, M., Palmu, A., Auranen, K., Zielhuis, GA and Kilpi, T. (2003) The effect of a pneumococcal conjugate vaccine on the risk of otitis media with effusion at 7 and 24 months of age. Int J Pediatr Otorhinolaryngol, 67, pp. 1235-1242.
19. Wisloff, T., Abrahamsen, TG, Bergsaker, MA, Lovoll, O., Moller, P., Pedersen, MK and Kristiansen, IS (2005) Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination programme.
20. Hedlund, J., Sorberg, M., Henriques-Normark, B. and Kronvall, G. (2003) Capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae among children in Sweden. Scand J Infect Dis, 35, pp. 452-458.
21. Harvard Centre for Risk Analysis (2005)
22. Salo, H., Sintonen, H., Nuorti, JP, Linna, M., Nohynek, H., Verho, J. and Kilpi, T. (2005) Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis, 37, pp. 821-832.
23. Swedish Statistics
24. Neumark, T., Molstad, S., Rosen, C., Persson, LG, Torngren, A. Brudin, L. et al. Evaluation of phenoxymethylpencillin treatment of acute otitis media in children aged 2-16 y.
25. Hjalte, K., Hjelmgren, J., Johansson, F. and Perssoon, U. (2005) Betalningsviljan for ett kvalitetsjusterat levnadsär- en pilotstudie. p. 1.
26. Rawlins, MD and Culyer, AJ. (2004) National Institute for Clinical Excellence and its value judgments. Br Med J, 329, pp. 224-227.
27. Persson, U. and Hjelmgren, J. (2003) Halso-och sjukvälrden behover kunskap om hur befolkningen varderar halsan. Lakartidningen, 43, pp. 3436-3437.
28. Beutels, P., Thiry, N. and van Damme, P. (2007) Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: A review (2002-2006). Vaccine, 25, pp. 1355-1367.